Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5

Experimental and Molecular Medicine

Volumn 43, Issue 1, 2011, Pages 24-34

  Kang, You Jung ^a   Kim, In Young ^a   Kim, Eun Hee ^a   Yoon, Mi Jin ^a   Kim, Seung U ^b   Kwon, Taeg Kyu ^c   Choi, Kyeong Sook ^a  

^a Ajou University School of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Keimyung University School of Medicine   (South Korea)

Author keywords

Apoptosis; Astrocytes; Glioma; Paxilline; TNF related apoptosis inducing ligand

Indexed keywords

CASPASE 3; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PAXILLINE; PROTEASOME; PROTEIN P20; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SURVIVIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING;

PENICILLIUM PAXILLI;

EID: 79251613261     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2011.43.1.003     Document Type: Article

References (32)

1. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7:542-7
2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62
4. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981;35:269-335
5. Bilmen JG, Wootton LL, Michelangeli F. The mechanism of inhibition of the sarco/endoplasmic reticulum Ca2+ ATPase by paxilline. Arch Biochem Biophys 2002;406:55-64
6. Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC, Mihatsch MJ, Kunzelmann K, Bubendorf L. KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene 2007;26:2525-34
7. Coiret G, Borowiec AS, Mariot P, Ouadid-Ahidouch H, Matifat F. The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells. Mol Pharmacol 2007;71:843-51
8. Galvez A, Gimenez-Gallego G, Reuben JP, Roy-Contancin L, Feigenbaum P, Kaczorowski GJ, Garcia ML. Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem 1990;265:11083-90
9. Goeger DE, Riley RT, Dorner JW, Cole RJ. Cyclopiazonic acid inhibition of the Ca2+-transport ATPase in rat skeletal muscle sarcoplasmic reticulum vesicles. Biochem Pharmacol 1988;37:978-81
10. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 2001;61:1162-70
11. He Q, Lee DI, Rong R, Tu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussaom A, Sheikh MS. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 2002;21:2623-33
12. Huang L, Xu J, Li K, Zheng MH, Kumta SM. Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone. Bone 2004;34:971-81
13. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5
14. Kaddour-Djebbar I, Lakshmikanthan V, Shirley RB, Ma Y, Lewis RW, Kumar MV. Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer. Mol Cancer Ther 2006;5:1958-66
15. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-5
16. Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS, Choi KS. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005;24: 6877-89
17. Kim SU, Moretto G, Lee V, Yu RK. Neuroimmunology of gangliosides in human neurons and glial cells in culture. J Neurosci Res 1986;15:303-21
18. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-20
19. Knaus HG, McManus OB, Lee SH, Schmalhofer WA, Garcia-Calvo M, Helms LM, Sanchez M, Giangiacomo K, Reuben JP, Smith AB 3rd, et al. Tremorgenic indole alkaloids potently inhibit smooth muscle high-conductance calcium- activated potassium channels. Biochemistry 1994;33: 5819-28
20. Kovacs GG, Zsembery A, Anderson SJ, Komlosi P, Gillespie GY, Bell PD, Benos DJ, Fuller CM. Changes in intracellular Ca2+ and pH in response to thapsigargin in human glioblastoma cells and normal astrocytes. Am J Physiol Cell Physiol 2005;289:C361-71
21. Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 2008;10:198-206
22. Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 1991;266:17067-71
23. Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 2007;7:519-30
24. Sanchez M, McManus OB. Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology 1996;35:963-8
25. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAILinduced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21
26. Sohn J, Khaoustov VI, Xie Q, Chung CC, Krishnan B, Yoffe B. The effect of ursodeoxycholic acid on the survivin in thapsigargin-induced apoptosis. Cancer Lett 2003;191: 83-92
27. Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One 2010;5:e11865
28. Weaver AK, Liu X, Sontheimer H. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J Neurosci Res 2004;78:224-34
29. Weller RO. Brain tumors in man. Food Chem Toxicol 1986;24:91-8
30. Yin LT, Fu YJ, Xu QL, Yang J, Liu ZL, Liang AH, Fan XJ, Xu CG. Potential biochemical therapy of glioma cancer. Biochem Biophys Res Commun 2007;362:225-9
31. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizytani Y, Miki T, Skai T. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/Enhancer-binding protein homologous protein. Cancer Res 2005;65:5662-7
32. Ziegler DS, Kung AL, Kieran MW. Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 2008;26:493-500